MAPT and Alzheimer disease: These markers associate with AD‐specific cerebral Abeta and tau aggregation (Abeta42/40 and P‐tau isoforms), or with parallel and/or downstream biological processes of neurocognitive disorders such as reactive astrocytosis and neurodegeneration (GFAP and NfL, respectively).10, 11